About Rachael Brake

An experienced drug developer dedicated to improving patients lives by identifying novel therapeutic options. Recognized as having strong scientific and technical knowledge of nonclinical and clinical development. Fluent in various R&D concepts and the application of these concepts to the commercial landscape.

Dedicated to using knowledge, thought and discussion to create and execute comprehensive drug development strategies. Recognized for harnessing diversity in multidisciplinary teams and supporting innovation. A strong communicator with a proven track record of success.

Deliverables

2020: Led the Alunbrig (brigatinib) development team through the Frontline approval of Alunbrig in ALK+ NSCLC based on the ALTA-1L trial

2019: Externalization of TAK-580 to Day One Therapeutics. DAY101 (TAK-580) is an oral and highly selective investigational pan-RAF inhibitor

2018: Led the late portfolio entry of Mobocertinib (TAK-788/ AP32788) an EGFR/ HER2 TKI targeting exon 20 insertions

2016: Supported the acquisition of ARIAD pharmaceuticals by Takeda

2013: Contributed to the development of a successful Novel:Novel IND submission combining two novel (unapproved) agents together in a single clinical development strategy

2012: Integrated the clinical development candidates Sapanisertib (mTORC1/2 inhibitor) and MLN1117 (a PI3K alpha inhibitor) into the Millennium pipeline after the acquisition of Intellikine

2011: Externalized TSR-011 an Anaplastic lymphoma kinase (ALK) inhibitor from Amgen to Tesaro biosciences

2011: Contributed to the delivery of the oncology clinical candidate AMG 319. In Phase 1 in 2011. A PI3K delta small molecule

2008: Contributed to the regulatory approval of Kepivance®, a therapeutic FGF protein. launched in 2005 by Amgen and partnered with Biovitrum in 2008